Thalidomide: from tragedy to promise | Zendy

Roger von Moos | Zendy; Rahel Stolz | Zendy; Thomas Cerny | Zendy; Silke Gillessen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Thalidomide: from tragedy to promise

Author(s) -

Roger von Moos,

Rahel Stolz,

Thomas Cerny,

Silke Gillessen

Publication year - 2003

Publication title -

schweizerische medizinische wochenschrift

Language(s) - English

Resource type - Journals

ISSN - 0036-7672

DOI - 10.4414/smw.2003.09947

Subject(s) - thalidomide , medicine , mechanism of action , drug , pharmacology , mechanism (biology) , action (physics) , immunology , multiple myeloma , biochemistry , epistemology , biology , in vitro , philosophy , physics , quantum mechanics

Thalidomide is an immunomodulatory and antiangiogenic drug. Although the exact mechanism of action is not fully understood, it has been shown to be active in a variety of diseases. There are multiple trials going on to evaluate the optimal dose of thalidomide and the importance of combining thalidomide with other drugs. This review introduces the properties and putative mechanism of action of thalidomide and summarizes the most important clinical trials with this biological modifier.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research